SGLT2 inhibitors endorsed for NHS use as monotherapies

Canagliflozin, dapagliflozin and empagliflozin have been recommended by NICE as options for treating type II diabetes as single agents when certain other treatments are unsuitable.

SGLT2 inhibitors are used when blood glucose levels are not adequately controlled by dietary measures and exercise alone, and other treatments are unsuitable. | iStock
SGLT2 inhibitors are used when blood glucose levels are not adequately controlled by dietary measures and exercise alone, and other treatments are unsuitable. | iStock

The SGLT2 inhibitors can be prescribed on the NHS as an alternative to dipeptidyl peptidase 4 inhibitors for patients whose blood glucose levels are not adequately controlled by dietary changes and exercise alone, in whom metformin is contraindicated or not tolerated and a sulfonylurea or pioglitazone is not appropriate.

Further information
View SGLT2 inhibitor drug records
NICE technology appraisal TA390
MIMS Diabetes Clinic

"For many people whose blood glucose levels aren't controlled by diet and exercise alone, metformin is the first drug treatment that they'll be offered. But some people may experience nausea and diarrhoea, and they may not be able to take it if they have kidney damage," said Professor Carole Longson, director of the NICE Centre for Health Technology Evaluation. "The committee agreed that people with diabetes and their clinicians would value having an additional treatment option to help manage their type 2 diabetes – which this positive guidance provides."

Canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance), which work by increasing urinary glucose excretion via inhibition of the SGLT2 sodium-glucose co-transporter, are already approved by NICE to treat patients with type II diabetes in combination with metformin (when there is a risk of hypoglycaemia or sulfonylureas are unsuitable), or together with insulin.

Canagliflozin and empagliflozin can also be prescribed on the NHS as triple therapy with metformin and a sulfonylurea, or metformin and pioglitazone.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more